Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Sun Pharma Advanced Research Co. Ltd. ( (IN:SPARC) ) is now available.
Sun Pharma Advanced Research Company Limited announced that its board has approved the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, at a meeting held on February 9, 2026. The results, reviewed by the statutory auditors with no material misstatements noted, have been filed with the stock exchanges and published on the company’s website, reinforcing regulatory compliance and financial disclosure transparency.
An independent limited review by S R B C & CO LLP confirmed that the interim financial statements comply with Indian Accounting Standards and SEBI listing requirements, without raising any qualifications. The timely completion of the board meeting and clean review report support SPARC’s governance standards and provide investors and other stakeholders with moderated assurance on the company’s interim financial performance and reporting quality.
More about Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited (SPARC) operates in the pharmaceutical and drug discovery industry, focusing on advanced research and development of innovative therapies. The company develops specialty and novel drug delivery systems, targeting both domestic and global markets through standalone and consolidated operations.
Average Trading Volume: 557,952
Technical Sentiment Signal: Sell
Current Market Cap: 45.12B INR
For detailed information about SPARC stock, go to TipRanks’ Stock Analysis page.